UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

AMENDMENT NO. 1 TO

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2022

Todos Medical Ltd.

(Exact name of registrant as specified in its charter)

Israel	000-56026	n/a
(State or other jurisdiction	(Commission	IRS Employer
of incorporation or organization)	File Number)	Identification No.)

121 Derech Menachem Begin, 30th Floor

Tel Aviv, 6701203 Israel

(Address of principal executive offices)

Registrant’s telephone number, including area code: 972 (52) 642-0126

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Introduction

This Form 8-K/A is being filed to amend and restate the Company’s Form 8-K filed on September 1, 2022 (the “Original Form 8-K”) in order to (a) clarify certain items in the Original Form 8-K, and (b) to add Exhibit 10.2, Conversion and Lock-up Agreement, dated August 31, 2022.

Item 1.01 Entry into a Material Definitive Agreement

On August 30, 2022, Todos Medical USA, Inc., a wholly-owned subsidiary of Todos Medical Ltd.. (collectively, the “Company”) entered into a lease agreement (the “Lease”) with Industrial Property, LLC to lease approximately 15,200 rentable square feet and land of 5.9 acres located at 112 E. Industrial Boulevard, Cleburne, TX 76031 (the “Premises”) for botanical manufacturing facility in order to establish direct manufacturing capabilities for the Company’s newly formed manufacturing subsidiary Todos Botanicals, LLC. The Lease provides for full building access. The actual commencement dates are subject to timely completion of the Building and premises. The term of the lease commences on the Initial Commencement Date and runs 124 months, with a five year renewal option.

The rent obligations over the term are summarized below. The time periods and amounts set forth below assume an occupation date of September 1, 2022, and may be subject to adjustment according to the Lease, including the Company’s right to rent abatement or lease abandonment in certain circumstances if the premises are not adequately maintained. The Lease provides the Company with the option to purchase the facility for $4,000,000.

Start Date	End Date	Base Monthly Rent
9/1/2022	8/31/2023	$19,008.75
9/1/2023	8/31/2024	$19,579.01
9/1/2024	8/31/2025	$20,166.38
9/1/2025	8/31/2026	$20,771.37
9/1/2026	8/31/2027	$21,394.51

Pursuant to the Lease, the Company will also be responsible for its proportionate share of the Building’s operating expenses, including property taxes, of approximately $2,500 per month.

The Lease is furnished as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the Lease.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

Item 8.01 Other Items

On August 31, 2022, the Company entered into a lock up and leak-out agreement (the “Lock-up”) with an institutional investor (the “Investor”) who has beneficial ownership of less than 9.9% of the Company’s Ordinary Shares, totaling 99,124,203 Ordinary shares, and owns all remaining notes issued under financing agreements entered into in 2020 that are convertible into Ordinary Shares (the “2020 Notes”). Under the terms of the Lock-up, the Investor has agreed to limit monthly sales of Ordinary Shares to no more than the greater of (a) 15% of the monthly trading volume of the Ordinary Shares, or (b) 15,000,000 Ordinary Shares. In the event that the price of the Ordinary Shares rises to above $0.10 per share, then the Investor shall be limited to selling no more than 5% of the trading volume. Upon mutual agreement, the Company and the Investor, from time-to time, may increase the leak out limitations.

The Investor has agreed to a moratorium on conversion of all remaining 2020 Notes for 90 days, which may be extended for an additional 30 days.

In the event the Company completes an uplisting of its Ordinary Shares onto a national stock exchange in the United States during the term of the Lock-Up, then the Holder agrees that it will convert all of its debt into Series A Preferred Shares of the Company and enter into an additional 90-day restriction agreement on share sales with the Company’s underwriters.

In addition, the $1,250,000 PCR equipment financing loan entered into in November 2020 has now been extinguished.

The Company has agreed to pay Holder $100,000 in cash in exchange on the day that is 5 days from the execution of the Lock-Up, and an additional $100,000 on the day that is 30 days from the Lock-Up.

Concurrently, the Company confirms that all convertible notes issued under financing agreements entered into in 2021 (the “2021 Notes”) have exercised their right to adjust their conversion price to $0.04792 per Ordinary share. Ordinary shares underlying the 2021 Notes were registered on Form S-1 that was declared effective on February 4, 2022.

The Lock-Up is furnished as Exhibit 10.2 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description of the Lock-Up does not purport to be complete and is qualified in its entirety by reference to the Lock-Up.

No.		Description
10.1		Commercial Lease Agreement, dated August 30, 2022, by and between Industry Property LLC and Todos Medical USA, Inc.
10.2		Conversion and Lock-up Agreement, dated August 31, 2022, by and between Todos Medical Ltd. and Leviston Resources LLC.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 12, 2022

	TODOS MEDICAL LTD.

	By:	/s/ Gerald Commissiong
		Gerald Commissiong
		Chief Executive Officer

-3-

TODOS MEDICAL LTD. 8-K/A